Truist Financial Has Lowered Expectations for Pediatrix Medical Group (NYSE:MD) Stock Price

Pediatrix Medical Group (NYSE:MD) had its price target cut by Truist Financial from $18.00 to $16.00 in a report published on Friday morning,Benzinga reports. They currently have a hold rating on the stock.

Several other analysts have also recently issued reports on MD. StockNews.com upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research note on Wednesday, January 22nd. Macquarie began coverage on shares of Pediatrix Medical Group in a research report on Monday, December 16th. They set an “outperform” rating and a $18.00 price target on the stock. Finally, UBS Group raised their target price on shares of Pediatrix Medical Group from $16.50 to $18.50 and gave the stock a “neutral” rating in a report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $16.75.

Pediatrix Medical Group Stock Down 1.5 %

MD opened at $13.35 on Friday. The firm has a 50 day moving average price of $14.33 and a 200 day moving average price of $13.91. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.42 and a current ratio of 1.60. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $17.67. The company has a market cap of $1.15 billion, a PE ratio of -11.13, a price-to-earnings-growth ratio of 1.74 and a beta of 1.32.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Thursday, February 20th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.12. Pediatrix Medical Group had a negative net margin of 4.92% and a positive return on equity of 15.47%. The company had revenue of $502.36 million during the quarter, compared to the consensus estimate of $486.22 million. Sell-side analysts expect that Pediatrix Medical Group will post 1.38 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Nomura Asset Management Co. Ltd. boosted its holdings in Pediatrix Medical Group by 95.3% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 2,500 shares of the company’s stock valued at $33,000 after purchasing an additional 1,220 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in Pediatrix Medical Group by 36.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 3,919 shares of the company’s stock valued at $51,000 after acquiring an additional 1,040 shares during the last quarter. AlphaQuest LLC increased its holdings in Pediatrix Medical Group by 65.9% in the fourth quarter. AlphaQuest LLC now owns 5,066 shares of the company’s stock valued at $66,000 after purchasing an additional 2,012 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Pediatrix Medical Group by 750.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 6,901 shares of the company’s stock valued at $91,000 after acquiring an additional 6,090 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in Pediatrix Medical Group by 218.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,445 shares of the company’s stock worth $98,000 after purchasing an additional 5,104 shares during the period. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.